21987-29-1

Basic information

• Product Name: 4,4-DIFLUOROPIPERIDINE
• Synonyms: 4,4-DIFLUOROPIPERIDINE;Piperidine, 4,4-difluoro-
• CAS NO: 21987-29-1
• Molecular Formula: C₅H₉F₂N
• Molecular Weight: 121.13
• Product Categories: pharmacetical;Pharmaceutical intermediate
• Mol File: 21987-29-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 34°C 12mm
• Flash Point: 22.931 °C
• Appearance: /
• Density: 1.089 g/cm³
• Vapor Pressure: 20mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• PKA: 8.20±0.10(Predicted)
• CAS DataBase Reference: 4,4-DIFLUOROPIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4,4-DIFLUOROPIPERIDINE(21987-29-1)
• EPA Substance Registry System: 4,4-DIFLUOROPIPERIDINE(21987-29-1)

Safety Data

• Statements: 36/37/38
• Safety Statements: 16-26-36/37/39
• Hazardous Substances Data: 21987-29-1(Hazardous Substances Data)

Usage

General Description

4,4-Difluoropiperidine is a chemical compound that is primarily known for its usage in pharmaceutical and medical research. It exists as a clear or slightly yellow liquid and has the molecular formula C5H10F2N. The compound is produced through a complex process that involves the interaction of certain chemical agents and solvents. It is classified as an organic compound with piperidines as its main functional group, which contributes largely to its properties and characteristics. There's limited information about its impact on human health, but guidelines on managing hazardous substances imply potentially harmful if inhaled, ingested, or makes contact with skin and eyes. Thus, it is crucial for researchers and anyone who will be in contact with the substance to follow safety guidelines and use necessary protective equipment and methods for handling the chemical.

InChI:InChI=1/C5H9F2N/c6-5(7)1-3-8-4-2-5/h8H,1-4H2/p+1

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 144230-52-4 4,4-difluoropiperidine hydrochloride 
• 281652-10-6 4,4-difluoropiperidine-1-formic acid tert-butyl ester 
• 39742-60-4 1-(2-phenylethyl)-4-piperidinone 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 155137-18-1 1-benzyl-4,4-difluoropiperidine 

Downstream Products

• 1123215-79-1 4,4-difluoro-1-[2-(4-nitro-phenyl)-ethyl]-piperidine 
• 1400654-76-3 C₂₂H₂₉F₂N₃O₄ 

Relevant articles and documents

Synthesis method of 4,4-difluoropiperidine-1-formyl chloride

The invention discloses a synthesis method of 4,4-difluoropiperidine-1-formyl chloride. The synthesis method comprises the following steps that first, a compound I, namely benzylpiperidin-4-one, and afluorine reagent are deoxidized and fluorated in a firs

QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS

The present invention is related to novel compounds of formula (I) having P2X7 antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans. (I)

Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl] piperidine series of histamine H3 receptor antagonists

A novel series of histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine template displaying low CYP2D6 and CYP3A4 inhibitory profiles has been identified. Structural features responsible for the reduction of P450 activity, a typical liability of 4-substituted imidazoles, have been established.